Chardan analyst Keay Nakae downgraded Korro Bio (KRRO) to Neutral from Buy with a $7 price target The firm views the negative Phase I/IIa REWRITE trial evaluating KRRO-110 as a “significant setback” for the company. It will require new human clinical data, which now is in 2027, to rebuild investor confidence in Korro’s OPERA design platform, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KRRO: